Treatment with anti‐PD‐1 and sICAM‐1 enhanced the anti‐tumor effects in anti‐PD‐1‐sensitive and ‐resistant mouse cancer models, indicating that ICAM‐1 restored anti‐PD‐1 efficacy. This evidence concerns the gene ICAM1 and neoplasm.